SON-1010 + Atezolizumab
Platinum-Resistant Ovarian Cancer (PROC)
Phase 1Active - Under evaluation per agreement with Roche
Key Facts
Indication
Platinum-Resistant Ovarian Cancer (PROC)
Phase
Phase 1
Status
Active - Under evaluation per agreement with Roche
Company
About Sonnet BioTherapeutics
Sonnet BioTherapeutics leverages its modular FHAB technology to create a pipeline of cytokine-derived therapies aimed at improving the therapeutic window and efficacy of immunomodulatory drugs in oncology. The company's lead program is in Phase 1 development with a combination study involving Roche's atezolizumab, and it has established collaborations for investigator-initiated trials. Following a recent business combination with Hyperliquid Strategies Inc., the company now trades on the Nasdaq Capital Market under the ticker 'PURR', positioning it to advance its clinical-stage pipeline.
View full company profile